首页 > 市场调查报告书 > 医疗设备

生技设备

市场调查报告书

商品编码

1475233

全球支原体诊断市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

Global Mycoplasma Diagnostics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年04月01日 | 出版商:

Value Market Research | 英文 218 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球支原体诊断市场需求预计将从 2023 年的 19.8 亿美元达到近 40 亿美元的市场规模，2024 年至 2032 年研究期间复合年增长率为 8.12%。

支原体诊断是指用于检测和识别支原体种类的实验室测试和方法，支原体是一组可以感染人类、植物和动物的细菌。细胞培养、生物製药、疫苗和其他生物製品中的支原体污染可能会损害研究的完整性、产品品质和安全性，因此准确可靠的诊断至关重要。支原体检测方法可能包括基于培养的技术、聚合酶链反应 (PCR)、酶联免疫吸附测定 (ELISA)、DNA 染色和核酸扩增测试 (NAAT)。

市场动态

人类和动物支原体感染的盛行率不断增加，以及人们对这些感染相关潜在健康风险的认识不断提高，推动了对准确可靠的诊断测试的需求。众所周知，支原体可引起多种呼吸系统、泌尿生殖系统和全身性疾病，因此及时且准确的诊断对于采取适当的治疗和感染控制措施至关重要。此外，由于对传染病快速且准确诊断的需求，临床环境中对现场护理和快速诊断测试的需求不断增长，推动了支原体诊断检测的开发和商业化。此外，分子和血清学检测技术的进步，例如聚合酶链反应（PCR）、酶联免疫吸附测定（ELISA）和核酸扩增检测（NAAT），提高了支原体诊断检测的灵敏度、特异性和周转时间，改善患者治疗效果并降低医疗成本。

此外，由于控製家畜和伴侣动物支原体感染的需要，支原体诊断在兽医和畜牧业实践中越来越多地采用，有助于市场成长。由于支原体感染对农业和水产养殖业造成重大经济损失，对准确有效的诊断工具来管理这些感染的需求持续成长。此外，新型支原体物种和抗生素抗药性菌株的出现进一步强调了不断创新和开发支原体诊断方法以应对不断变化的诊断挑战的重要性。然而，替代诊断技术和新测试方法的进步可能会在未来几年挑战支原体诊断市场的成长，因为这些创新可以提供更快、更具成本效益或更准确的诊断解决方案。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具还对全球支原体诊断市场的每个细分市场进行了包容性评估。支原体诊断产业的成长和趋势为本研究提供了整体方法。

市场区隔

支原体诊断市场报告的这一部分提供了国家和区域级别细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人口统计数据以及即将到来的机会。

按产品分类

试剂盒和试剂
仪器
软体与服务

依技术

聚合酶炼式反应
免疫测定（ELISA、RIA）
DNA染色
微生物培养技术
其他的

按最终用户

医院
诊断实验室
诊所
其他的

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲支原体诊断市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。支原体诊断市场的主要参与者包括 Merck & Co., Inc.、F. Hoffmann-La Roche AG、Agilent Technologies、Sartorius AG、Savyon Diagnostics、Takara Bio Inc.（Takara Holding Company Inc.）、Lonza Group、Charles River Laboratories International, Inc.、Thermo Fisher Scientific Inc.、PromoCell GmbH。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区按国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲按国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 9 章：支原体诊断公司的竞争格局

支原体诊断市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 10 章：公司简介

顶级公司市占率分析
市场集中度
Merck & Co. Inc.

公司简介
公司收入
产品
最近的发展

F. Hoffmann-La Roche AG

公司简介
公司收入
产品
最近的发展

Agilent Technologies

公司简介
公司收入
产品
最近的发展

Sartorius AG

公司简介
公司收入
产品
最近的发展

Savyon Diagnostics

公司简介
公司收入
产品
最近的发展

Takara Bio Inc. (Takara Holding Company Inc.)

公司简介
公司收入
产品
最近的发展

Lonza Group

公司简介
公司收入
产品
最近的发展

Charles River Laboratories International Inc.

公司简介
公司收入
产品
最近的发展

Thermo Fisher Scientific Inc.

公司简介
公司收入
产品
最近的发展

PromoCell GmbH

公司简介
公司收入
产品
最近的发展

註 - 在公司概况中，财务详细资料和最新进展视情况而定，或对私人公司而言可能不包括在内

简介目录图表

Product Code: VMR112114318

The global demand for Mycoplasma Diagnostics Market is presumed to reach the market size of nearly USD 4 Billion by 2032 from USD 1.98 Billion in 2023 with a CAGR of 8.12% under the study period 2024 - 2032.

Mycoplasma diagnostics refers to laboratory tests and methods used to detect and identify mycoplasma species, a group of bacteria that can infect humans, plants, and animals. Mycoplasma contamination in cell cultures, biopharmaceuticals, vaccines, and other biological products can compromise research integrity, product quality, and safety, making accurate and reliable diagnostics essential. Mycoplasma detection methods may include culture-based techniques, polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA), DNA staining, and nucleic acid amplification tests (NAATs).

MARKET DYNAMICS

The increasing prevalence of mycoplasma infections in humans and animals and the rising awareness of the potential health risks associated with these infections drive the demand for accurate & reliable diagnostic tests. Mycoplasma species are known to cause a wide range of respiratory, genitourinary, and systemic diseases, making timely and accurate diagnosis essential for appropriate treatment and infection control measures. Additionally, the growing demand for point-of-care and rapid diagnostic tests in clinical settings, driven by the need for quick and accurate diagnosis of infectious diseases, fuels the development and commercialization of mycoplasma diagnostic assays. Moreover, advancements in molecular and serological testing technologies, such as polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA), and nucleic acid amplification tests (NAATs), enhance the sensitivity, specificity, and turnaround time of mycoplasma diagnostic tests, improving patient outcomes and reducing healthcare costs.

Furthermore, the increasing adoption of mycoplasma diagnostics in veterinary medicine and animal husbandry practices, driven by the need to control mycoplasma infections in livestock and companion animals, contributes to market growth. With mycoplasma infections posing significant economic losses in the agriculture and aquaculture industries, the demand for accurate & efficient diagnostic tools to manage these infections continues to rise. Moreover, the emergence of novel mycoplasma species and antibiotic-resistant strains further underscores the importance of continuously innovating and developing mycoplasma diagnostics to address evolving diagnostic challenges. However, advancements in alternative diagnostic technologies and new testing methods may challenge the mycoplasma diagnostics market growth in the coming years, as these innovations could offer faster, more cost-effective, or more accurate diagnostic solutions.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of mycoplasma diagnostics. The growth and trends of mycoplasma diagnostics industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the mycoplasma diagnostics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

Kits & Reagents
Instruments
Software & Services

By Technology

PCR
Immunoassay (ELISA, RIA)
DNA Staining
Microbial Culture Techniques
Others

By End-User

Hospitals
Diagnostic Laboratories
Clinics
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Mycoplasma Diagnostics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Mycoplasma Diagnostics market include Merck & Co., Inc., F. Hoffmann-La Roche AG, Agilent Technologies, Sartorius AG, Savyon Diagnostics, Takara Bio Inc. (Takara Holding Company Inc.), Lonza Group, Charles River Laboratories International, Inc., Thermo Fisher Scientific Inc., PromoCell GmbH. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. MYCOPLASMA DIAGNOSTICS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product
- 3.7.2 Market Attractiveness Analysis By Technology
- 3.7.3 Market Attractiveness Analysis By End-user
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL MYCOPLASMA DIAGNOSTICS MARKET ANALYSIS BY PRODUCT

5.1. Overview By Product
5.2. Historical and Forecast Data
5.3. Analysis By Product
5.4. Kits & Reagents Historic and Forecast Sales By Regions
5.5. Instruments Historic and Forecast Sales By Regions
5.6. Software & Services Historic and Forecast Sales By Regions

6. GLOBAL MYCOPLASMA DIAGNOSTICS MARKET ANALYSIS BY TECHNOLOGY

6.1. Overview By Technology
6.2. Historical and Forecast Data
6.3. Analysis By Technology
6.4. PCR Historic and Forecast Sales By Regions
6.5. Immunoassay (ELISA, RIA) Historic and Forecast Sales By Regions
6.6. DNA Staining Historic and Forecast Sales By Regions
6.7. Microbial Culture Techniques Historic and Forecast Sales By Regions
6.8. Others Historic and Forecast Sales By Regions

7. GLOBAL MYCOPLASMA DIAGNOSTICS MARKET ANALYSIS BY END-USER

7.1. Overview By End-user
7.2. Historical and Forecast Data
7.3. Analysis By End-user
7.4. Hospitals Historic and Forecast Sales By Regions
7.5. Diagnostic Laboratories Historic and Forecast Sales By Regions
7.6. Clinics Historic and Forecast Sales By Regions
7.7. Others Historic and Forecast Sales By Regions

8. GLOBAL MYCOPLASMA DIAGNOSTICS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE MYCOPLASMA DIAGNOSTICS COMPANIES

9.1. Mycoplasma Diagnostics Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF MYCOPLASMA DIAGNOSTICS INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Merck & Co. Inc.
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. F. Hoffmann-La Roche AG
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Agilent Technologies
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Sartorius AG
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Savyon Diagnostics
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Takara Bio Inc. (Takara Holding Company Inc.)
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Lonza Group
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Charles River Laboratories International Inc.
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Thermo Fisher Scientific Inc.
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. PromoCell GmbH
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments